A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL
Study Start Date
Actual Primary Completion Date
Resource links provided by the National Library of Medicine
Safety evaluation assessed by dose limiting toxicity within first cycle of 28 day treatment and AEs within 3 cycles [ Time Frame: every first 28 days ]
Pharmacokinetic (PK) profile of single and multiple doses [ Time Frame: day 1 and 15 of cycle 1,day 6, 8, 10, 12, 22 and 28 of cycle 1, day 15 of cycle 2 ]
Secondary Outcome Measures
Anti-leukemic activity within 3 cycles of 28 days treatment [ Time Frame: Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study completion ]
Bone marrow and/or blood assessments to detect the presence of Bcr-Abl transcript and mutational analysis of Bcr-Abl before, during and after therapy. [ Time Frame: Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study comp ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed as Ph+ ALL who are either relapsed after or refractory to standard therapy
Diagnosed as CML in blast crisis or accelerated phase or chronic phase who are resistant or intolerant to imatinib
Performance status is normal or ambulatory and capable of all self-care Exclusion Criteria
A history of significant or serious uncontrolled cardiovascular disease
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib
Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control
Cytopathologically confirmed CNS infiltration NB: in absence of suspicion of CNS involvement, lumbar puncture is not required
Impaired cardiac function, including any one of the following
LVEF < 45% as determined by echocardiogram
Complete left bundle branch block
Use of a cardiac pacemaker
ST depression of > 1mm in 2 or more leads and/or T-wave inversions in 2 or more contiguous leads
Congenital long QT syndrome
History of or presence of significant ventricular or atrial tachyarrhythmias
Clinically significant resting bradycardia (< 50 beats per minute)
QTc > 480 msec on screening ECG (using the QTcF formula)
Right bundle branch block plus left anterior hemiblock, bifascicular block
Myocardial infarction within 3 months prior to starting AMN107
Uncontrolled angina pectoris
Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AMN107 (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
Use of therapeutic warfarin
Acute or chronic liver or renal disease considered unrelated to tumor (e.g., hepatitis, cirrhosis, renal insufficiency, etc.)
Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF) ≤ 1 week prior to starting study drug.
Patients who are currently receiving treatment with any of the medications listed in (cf. Post-text suppl. 5) that cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in (cf. Post-text suppl. 5) have the potential to prolong the Q-T interval.
Patients who have received chemotherapy ≤ 1 week or who are within 5 half-lives of their last dose chemotherapy (6 weeks for nitrosurea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy. Hydroxyurea is permitted at the investigator's discretion prior to enrollment.
Patients who have received Glivec® ≤ 1 week or who have not recovered from side effects of such therapy.
Patients who have received immunotherapy ≤ 1 week prior to starting study drug or who have not recovered from side effects of such therapy.
Patients who have received any investigational drug (excluding STI571/Glivec) ≤ 4 weeks or investigational cytotoxic agent within 1 week (or who are within 5 half-lives of a previous investigational cytotoxic agent) prior to starting study drug or who have not recovered from side effects of such therapy.
Patients who have received wide field radiotherapy ≤ 4 week or limited field radiation for palliation ≤ 2 week prior to starting study drug or who have not recovered from side effects of such therapy.
Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of AMN107). Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug
Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.
Patients unwilling or unable to comply with the protocol
Other protocol-defined inclusion and exclusion criteria may apply.